Who Paid My Doc
Jesse Shaw
Sports Medicine Pullman, WA Doctor of Osteopathy
NPI 1912293572 CMS profile 930117
825 Se Bishop Blvd Ste 120, Pullman, WA 99163
General payments
$82
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jesse Shaw of Pullman, WA is reported in the CMS Open Payments database as having received $82 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 21st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $20 | 1 | |
| 2024 | General | $36 | 1 | |
| 2019 | General | $25 | 1 |
Beside peers
- Jesse Shaw
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to Jesse Shaw were reported at $20. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.
Show as a table
| Year | Jesse Shaw | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $25 | $119 | $35–$362 | $163 |
| 2020 | $0 | $77 | $24–$275 | $114 |
| 2021 | $0 | $104 | $28–$340 | $132 |
| 2022 | $0 | $94 | $31–$272 | $149 |
| 2023 | $0 | $91 | $34–$271 | $160 |
| 2024 | $36 | $126 | $38–$294 | $164 |
| 2025 | $20 | $114 | $39–$293 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$29,070
Medicare patients
168
Services billed
1,624
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 74% | |
| High blood pressure | 58% | |
| Atrial fibrillation | 15% | |
| Diabetes | 13% | |
| Cancer | 13% | |
| Osteoporosis | 12% | |
| Chronic kidney disease | 11% | |
| Ischemic heart disease | 10% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 | Office | 14 | 816 | $5,673 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 46 | 378 | $34 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Washington
Related records
Sports Medicine in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.